Monday, November 1, 2010 12:57 AM
|
Sherry Drew
http://www.isid.org PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY, MULTIPLE SCLEROSIS TREATMENT-ASSOCIATED The multiple sclerosis market is getting increasingly competitive, something that Wall Street believes could put some pressure on Tysabri. Novartis AG's ( NVS) Gilenya, the 1st oral therapy for the disease, was recently approved, and numerous other therapies are in development. As of 30 Jun 2010, 52 700 patients were using the drug around the world. In total, about 71 400 patients have used the drug since its launch. Of the total PML cases, 29 were in the U.S., 37 were in the European Union and 4 were in other areas. Looked at another way, the rate is about 1.44 cases per 1000 patients on the drug for between 2-3 years.
|